{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "marketState": "PRE", "exchange": "NCM", "regularMarketChangePercent": -3.5398197, "regularMarketPrice": 1.09, "firstTradeDateMilliseconds": 1395322200000, "priceHint": 4, "earningsTimestamp": 1683549000, "earningsTimestampStart": 1691006400, "earningsTimestampEnd": 1691438400, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.33, "epsForward": -0.16, "epsCurrentYear": -0.42, "priceEpsCurrentYear": -2.5952382, "sharesOutstanding": 185928000, "bookValue": -0.077, "fiftyDayAverage": 0.76094, "fiftyDayAverageChange": 0.32906002, "fiftyDayAverageChangePercent": 0.43243885, "twoHundredDayAverage": 0.53929, "twoHundredDayAverageChange": 0.55071, "twoHundredDayAverageChangePercent": 1.021176, "marketCap": 202661520, "forwardPE": -6.8125005, "priceToBook": -14.155845, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "3.0 - Hold", "tradeable": false, "cryptoTradeable": false, "shortName": "Akebia Therapeutics, Inc.", "longName": "Akebia Therapeutics, Inc.", "messageBoardId": "finmb_36644983", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChange": -0.03999996, "regularMarketTime": 1684180804, "regularMarketDayHigh": 1.1901, "regularMarketDayRange": "1.0501 - 1.1901", "regularMarketDayLow": 1.0501, "regularMarketVolume": 1717840, "regularMarketPreviousClose": 1.13, "bid": 0.0, "ask": 0.0, "bidSize": 22, "askSize": 32, "fullExchangeName": "NasdaqCM", "financialCurrency": "USD", "regularMarketOpen": 1.1, "averageDailyVolume3Month": 1631336, "averageDailyVolume10Day": 1491880, "fiftyTwoWeekLowChange": 0.84900004, "fiftyTwoWeekLowChangePercent": 3.5228217, "fiftyTwoWeekRange": "0.241 - 1.2", "fiftyTwoWeekHighChange": -0.110000014, "fiftyTwoWeekHighChangePercent": -0.091666676, "fiftyTwoWeekLow": 0.241, "fiftyTwoWeekHigh": 1.2, "displayName": "Akebia Therapeutics", "symbol": "AKBA"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "245 First Street", "address2": "Suite 1400", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "617 871 2098", "fax": "617 871 2099", "website": "https://www.akebia.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 204, "companyOfficers": [{"maxAge": 1, "name": "Mr. John P. Butler MBA", "age": 58, "title": "CEO, Pres & Director", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": {"raw": 1287060, "fmt": "1.29M", "longFmt": "1,287,060"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. David A. Spellman", "age": 46, "title": "Principal Accounting Officer, Sr. VP, CFO & Treasurer", "yearBorn": 1976, "fiscalYear": 2022, "totalPay": {"raw": 961925, "fmt": "961.92k", "longFmt": "961,925"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Michel  Dahan", "age": 43, "title": "Sr. VP & COO", "yearBorn": 1979, "fiscalYear": 2022, "totalPay": {"raw": 734726, "fmt": "734.73k", "longFmt": "734,726"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Nicole R. Hadas", "age": 49, "title": "Sr. VP, Chief Legal Officer & Sec.", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": {"raw": 687379, "fmt": "687.38k", "longFmt": "687,379"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Steven Keith Burke", "age": 61, "title": "Sr. VP of R&D and Chief Medical Officer", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": {"raw": 766574, "fmt": "766.57k", "longFmt": "766,574"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Tracey  Vetterick", "title": "VP of Portfolio Strategy & Corp. Admin.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mercedes  Carrasco", "title": "Director of Corp. Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Douglas  Jermasek M.B.A.", "age": 61, "title": "VP of Marketing & Strategy", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Meredith  Bowman", "title": "Sr. VP of People", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Kimberly  Garko", "title": "Sr. VP of Quality, Manufacturing & Pharmaceutical Devel.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 10, "boardRisk": 7, "compensationRisk": 7, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}